Intratumoral N17350 in Advanced Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this clinical trial is to learn if N17350 works to treat advanced solid tumors in adults. It will also learn about the safety of N17350 and help determine the best dose to use in future studies. The main questions it aims to answer are: 1. Does N17350 cause tumors to shrink or stop growing in some participants with advanced solid tumors? 2. Are there any side effects for participants when taking N17350? 3. What is the safest dose of N17350 and the dose that should be used for further study? 4. Researchers will give N17350 directly into tumor lesions using a needle (intratumoral injection). This is an open-label study, meaning all participants will receive N17350 and there is no placebo. Participants will: 1. Receive injections of N17350 into tumor lesions every second week for 8 or 12 weeks 2. Visit the clinic regularly for checkups, blood tests, and monitoring for side effects 3. Have imaging scans (such as CT or MRI) to measure tumors and assess response 4. Provide blood samples and, when required, tumor samples to help researchers understand how N17350 affects the tumor and the immune system
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Zdolność do podpisania zgody i uczestniczenia w badaniu
- •Zaawansowany nowotwór litego, który nie reaguje na standardowe leczenie lub pacjent go nie toleruje
- •Dobry stan ogólny (ECOG 0-1)
- •Mierzalne zmiany nowotworowe
- •Co najmniej jeden guz dostępny do wstrzyknięcia leku, bez ryzyka uszkodzenia dużych naczyń krwionośnych
- •Wyleczenie się z efektów ubocznych poprzedniego leczenia
- •Prawidłowe funkcjonowanie wątroby, nerek i krzepnięcia krwi
✗ Disqualifies
- •Poważne problemy psychiatryczne lub medyczne, które mogą utrudnić udział w badaniu
- •Historia przeszczepienia organu
- •Niedobór alfa-1 antytrypsyny
- •Zaburzenia krwawienia lub defekty krzepnięcia
- •Aktywna choroba autoimmunologiczna wymagająca leczenia w ciągu ostatnich 6 miesięcy
- •Wydłużony czas repolaryzacji serca (QTcF >480)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 13, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (6)
The Angeles Clinic and Research Institute
Los Angeles, United States
UCLA - Jonsson Comprehensive Cancer Center
Los Angeles, United States
University of California, San Francisco
San Francisco, United States
Roswell Park Comprehensive Cancer Center
Buffalo, United States
Calvary Mater Hospital
Newcastle, Australia
Westmead Hospital
Westmead, Australia
Trial contact
Onchilles Pharma Clinical Trials
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.